Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Close

Genmab AS (GMAB)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Genmab AS's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
28.97 +0.27    +0.94%
22/04 - Closed. Currency in USD ( Disclaimer )
Pre Market
29.20
+0.23
+0.79%
6:44:41 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 452,366
  • Bid/Ask: 28.84 / 28.87
  • Day's Range: 28.72 - 29.21
Genmab AS 28.97 +0.27 +0.94%

GMAB Balance Sheet

 
Featured here, the Balance Sheet for Genmab AS, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 4 period ending dates (either quarterly or annually).
AnnualQuarterly
InvestingPro Advanced Balance Sheet
Period Ending: 2023
31/12
2023
30/09
2023
30/06
2023
31/03
Total Current Assets 33139 33027 29749 28231
Cash and Short Term Investments 28135 27525 24884 24544
Cash - - - -
Cash & Equivalents 14867 14273 10874 12288
Short Term Investments 13268 13252 14010 12256
Total Receivables, Net 4947 5432 4814 3687
Accounts Receivables - Trade, Net 4947 5432 4690 3199
Total Inventory 57 70 51 -
Prepaid Expenses - - - -
Other Current Assets, Total - - - -
Total Assets 35289 35238 31978 30394
Property/Plant/Equipment, Total - Net 1641 1651 1634 1596
Property/Plant/Equipment, Total - Gross 2317 - - -
Accumulated Depreciation, Total -676 - - -
Goodwill, Net - - - -
Intangibles, Net 101 115 129 132
Long Term Investments 134 156 183 140
Note Receivable - Long Term - - 124 488
Other Long Term Assets, Total - - - -
Other Assets, Total 8652 8179 9530 8864
Total Current Liabilities 2484 2902 1993 1955
Accounts Payable - - - -
Payable/Accrued - - - -
Accrued Expenses - - - -
Notes Payable/Short Term Debt - - - -
Current Port. of LT Debt/Capital Leases 90 83 82 89
Other Current liabilities, Total 2394 2819 1911 1866
Total Liabilities 3679 4126 3223 3204
Total Long Term Debt 680 710 721 740
Long Term Debt - - - -
Capital Lease Obligations 680 710 721 740
Deferred Income Tax - - - -
Minority Interest - - - -
Other Liabilities, Total 515 514 509 509
Total Equity 31610 31112 28755 27190
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total 66 66 66 66
Additional Paid-In Capital 12461 12452 12412 12341
Retained Earnings (Accumulated Deficit) 19023 18452 16165 14666
Treasury Stock - Common - - - -
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) - - - -
Other Equity, Total 60 142 112 117
Total Liabilities & Shareholders' Equity 35289 35238 31978 30394
Total Common Shares Outstanding 65.33 65.32 65.28 65.22
Total Preferred Shares Outstanding - - - -
* In Millions of DKK (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

GMAB Comments

Write your thoughts about Genmab AS
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
David Klepetko
klepid Nov 10, 2021 11:45AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
ERs are out https://ir.genmab.com/financial-calendar
Jens Jensen
Jens Jensen Aug 11, 2021 3:39PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
And no debt, $3B cash position, one of the most "trending" technologies around (bispecific antibodies) and an impressive outflux of new drugs via seemingly peerpoor (now that's a nice new word - you're free to use it;-) quality of research. I urge everyone to check it out - heres the Investor Presentation for Q22021 "https://ir.genmab.com/static-files/cac2e584-6554-4637-a367-a5d21abc51e0". Comp value 2day $30B, best realistic ;-) guess is double up in 3-4 yrs. Seriously.
Jens Jensen
Jens Jensen Aug 11, 2021 3:14PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Falling.. standard market reaction these days to good and solid reportings: crazy that is.. in spite of improved revenue outlook, 4 drugs on market (darazalex(need I say more?)+3 soon-to-become-blockbusters) + 1 prob-to-market-in-october (tisotumab vedotin, w Seagen) + 2 new drugs revealed (one of which: inclacumab - a Sickle Cell Disease treatment, outlicensed to Roche and further outlicensed to Global Blood Therapeutics, but none the less - w potential for BB).
BumHunters Archer
JohnJenga Mar 10, 2021 8:45AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
32, 40 again soon
Morten Lyng
Morten Lyng May 28, 2020 4:18PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Luxus
Morten Lyng
Morten Lyng May 26, 2020 6:01PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Going 200 % up in the next 24-30 month
Mirko Prazzoli
Mirko Prazzoli May 12, 2020 12:45PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
what about this stock?
Morten Lyng
Morten Lyng May 02, 2020 3:32AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The best upcoming medico company for cancer
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email